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ABSTRACT
MULTIOBJECTIVE SIMULATION-BASED METHODOLOGIES

FOR
MEDICAL DECISION MAKING
By
Ahmed Hassan YoussefAgha

June 21,2006

A variety of methodologies have been employed for decision making related to
the treatment of diseaseslinjury. Decision trees are a functional way in which to examine
problems under uncertainty by providing a method to analyze decisions under risk
(Detsky, 1996,97). However, conventional decision trees do not completely represent
"the real world" since they cannot investigate problems that are cyclic in nature (Jaafari,
2003).
The stochastic tree that developed Hazen during 1992-to-1996 is one of the most
relevant methods and techniques related to decision analyses that append more
incorporation for medical intervention related to recurring diseaseslinjuries. "The
approach combines features of continuous-time Markov chains with those of decision
trees and that enable time to be modeled as a range where health state transitions can
occur at any instant" (Hazen 1992-to-96). It can also accommodate patients' preferences
regarding risk and quality of life.
The importance of Hazen's stochastic tree was mentioned in the technical report,
by Prof. Keefer et aI, Arizona State University, Summary of Decision Analysis

Applications in the Operations Research Literature on 1990-to-2001 (Keefer, 2002).
They stated that the work of Hazen, stochastic trees, is one of applications that presented
significant advancement in decision analysis methodological tools.
However, in medical decision making, Hazen stochastic tree model has some
limits and restrictions. Hazen stochastic tree can only utilize an exponential distribution
for health state sojourn, to simplify the rollback/recursive computations. Noticeably,
some diseaseslinjury can be best represented by distributions such as Weibull
distribution, Gamma distribution, Log-Logistic distribution, Log-Normal distribution,
and Coxian distribution (Collett, 1999). In addition, the stochastic tree modeling
technique does not have a method to correct differences between experimental
circumstances/conditions and the cOlTesponding circumstances/conditions of a
standard/current treatment.

In this research we enhance Hazen's stochastic tree by developing an analytical
model, and we extend its capabilities more by developing multi-objective simulation
based methodologists for medical decision making. First, with our enhancement on the
Hazen's stochastic tree, the model is improved by utilizing the Weibull Accelerated
Failure Time model. This new technique will fill the gap between the experimental
circumstances and the corresponding circumstances or conditions of standard/current
treatment. Second, as simulation can be a final alternative for problems that are
mathematically intractable for other techniques (Banks 1996), our multi-objective
simulation based model for medical decision making extends the capabilities of Hazen
stochastic tree. It adds more flexibility with the use of survival distributions for health

states sojourn, and combines two sound theories: multi attribute utility (MAU) theory,
and Ranking-Selection procedures.

Indeed, our simulation model (considering patient's profile/preferences and health
states survival/quality/cost, QALY) presents an investigation of the use of simulation on
the stochastic tree, with associated techniques related to ranking and selection, and multiobjectives decision analysis.

Key words: Stochastic Tree, Treatments Models, Simulation Methodologies,
Multi --objectives Decision Analysis, Patient's Profile, Patient's Preferences, Quality
Adjusted Life Year (QAL Y), Health States Cost.
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CHAPTER I
INTRODUCTION
Typical decision trees are a functional way in which to analyze problems under
uncertainty by providing a mechanism to analyze decisions under risk (Detsky 1996, 97).
Conventional decision trees examine complex issues composed of discrete sequential
events such as, undergoing tests, receiving the tests results, and deciding on the optimal
medical management. Conventional decision trees do not completely represent "the real
world" since they cannot investigate disorders that are cyclic in nature (Jaafari, 2003). As
a result, researchers have developed methodologies, via Markov processes, allowing for
the examination of cyclic problems or recurrent diseases.
Moreover, in medical decision making, decision trees models have some limits
and restrictions, such as having a low dimensional preference summary (e.g. memory
less, Markov, or Semi-Markov) to allow or feasibility for rollback calculations, lack of
filling the gap between the experimental and practical medical intervention, limits related
to specific survival distributions, and no capabilities to unify multiple performance
measures into one scalar. So, further work is required to add more capabilities and
extensions onto decision tree models to examine/study, accurately and with more reality,
the health outcomes of medical interventions associated with cyclic disorders or recurrent
diseases.

Simulation is "a broad collection of methods and applications to mimic the
behavior of real systems, usually on a computer with suitable software" (Kelton, 2001).
Simulation is a methodology that has advantages, such as: (a) simulation can be a
solution methodology of last alternative for problems that are mathematically intractable
for other techniques; (b) even for problems that are mathematically tractable, simulation
can often provide a higher level of detail than can other techniques. (c) Simulation can
sometimes provide (approximate) answers at a smaller cost/effort to some problems
which are fully tractable mathematically but whose solution may be cumbersome and
time consuming (Banks 1996). Other advantages of simulation include the facts that it
permits modification or design of medical intervention systems by trial and error, allows
for easy exploration of the system's sensitivity to changes in the input parameters, and
provides a highly controllable environment for experiments. Simulation can be valuable
to the operations researcher as a means of testing the applicability and validity of
mathematical models and expressions.
This study has two main parts: First, a special case analytical model is developed,
based on the earlier work of Hazen (1992-to-1996). Second, a simulation-based model is
developed for further study.
The stochastic tree model developed by Hazen combines features of continuoustime Markov chains with those of conventional decision trees to analyze cyclic disorders
and/or recurrent diseaseslinjuries (Hazen, 1992-1996).
Hazen's stochastic tree model allows health state transitions to occur at any
instant. Hazen's work, of stochastic tree, presents significant detail about a particular
decision analysis methodological and implementation issue: in particular Hazen
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described and presented the development and the use of a decision tree model; moreover,
it discussed in depth subjective utility/value functions and tradeoffs between attributes.
Hazen's stochastic tree technique resolved problems, related to recurrent diseases and
injuries, inherent in conventional decision analysis methodologies (Keefer, 2002).
The Hazen et al. model (Hazen, 1992-1996) maintains multiple input parameters
and one performance measure, at a time; and run within constraints for recursive
processing. In stochastic tree technique, the time spent in any health state is restricted to a
low-dimensional or tractable preference summary (e.g. memory less, Markov, and SemiMarkov) which guarantees both tractability recursive computations and convenience in
assessment. Hazen's stochastic tree mode can only utilize an exponential distribution for
health states stay time. Noticeably, some disorders can be best represented by different
distributions such as Weibull distribution, Gamma distribution, Log-Logistic distribution,
Log-Normal distribution, Coxian, and Quadratic distribution (Collett, 1999). In addition,
the stochastic tree modeling technique does not have a method to correct differences
between experimental circumstances/conditions and the corresponding circumstances
and/or conditions of the standard/current treatment.
A performance measure such as quality-adjusted life years (QAL Y) is the
measure of health benefit to an individuaL QALY reflects the gain in expected utility of
having some treatment. It can be used to represent utility only if individuals are willing to
trade off years of life in a given health state for fewer years at an ideal health state at a
constant rate, irrespective of the number of years spent in the state (Clarke 2004). In
addition, it would be beneficial if these methodologies integrate an individual's specific
health conditions such as smoking history, body mass index, and age.
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For the first part of this research, we extend Hazen's stochastic modeling
technique, which incorporates the memory-less exponential distribution by utilizing the
Weibull Accelerated Failure Time model (WAFT). The WAFT model is memory-less
when Weibull's shape parameter equals to one . This new technique includes health
conditions at the individual level and may not only provide a novel way in which to study
QAL Y or other medical intervention outcomes, but also it may provide a novel way in
which to analyze recurrent diseases. However, the enhanced model is still restricted to
have a particular tractable preference summary- represented in the use of WAFT with
shape parameter equals to one to fit with the memory less property the same as the use of
the exponential distribution- for facilitating rollback computations. Consequently, it was
still limited to the use of specific survival distributions, and had no capabilities to unify
multi-performance measures into one scalar at a time. So, further work was required to
add more capabilities and extensions not only for the related limitations on the use of
specific survival distribution, but also to add multiple performance measures.
Most of the ranking and selection (R&S) literature focuses on procedures that are
designed for scalar performance measures (Bechhofer, 1995). However, some
multivariate results do exist: Gupta (1979) described procedures that are based on scalar
functions of the mean and covariance matrix of the multivariate populations. These
procedures reduce the multivariate performance measure problem to a scalar performance
measure problem. The procedures described in Gupta, require a complicated step of
estimating a covariance matrix, and the approach does not belong to a class of procedures
whose properties are easy understood (Morrice 2001). Kim et al utilized a Maxi-Min
approach to optimize the characteristics of steel (Kim and Lin, 1999). Kim indicated, in
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some situations that a Maxi-Min method may cause an unreasonable decision because it
focuses on maximizing the poorest performing measure. For this reason, they advised
performing "several approaches for the final decision" (Kim 1999, page 8).
"In a medical related business setting, a different approach is often used: convert
project performance over multiple measures to a scalar measure using costs" (Morrice
2001, page 800). Even though this "costing" method of performance measures has
advantages, it has some disadvantages too. Not enough resources and not accurately
assigning a dollar value to intangibles and ambiguous measures (e.g., quality of life)
affect perfect cost even though the data resource available.

In our simulation modeling, we utilize an approach, similar to Morrice et al.
(Morrice 1998, 1999), to this problem: convert multiple performance measures to a scalar
performance measure using multiple attribute utility (MAU) theory (Keeney and Raiffa
1992). MAU theory can be used with or without costing approach when good cost data
are not available or when cost is not suitable as a measure of performance.
For the second part of this research, we extend Hazen's stochastic tree using
simulation model, MAU theory, and a statistical R&S with the indifference-zone
approach of (see Law and Kelton, 2000), to select the best medical intervention
configuration from a set of n configurations when a medical intervention performance is
determined by m > 1 performance measures. In other words, we developed a simulation
model that maintains multiple input parameters and multiple performance measures.
Chapter2-Literature Review contains seven main sections: Decision Tree and
Stochastic Tree, Markov Models, Survival Analyses, Screening and Ranking-Selection
Procedures, Multiple Attribute Utility Theory, and Simulation. Each section defines,
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describes, and illustrates the advantages and the disadvantages of the related decision
model. Chapter3-Methods is divided into two parts. For the first part, four main sections
explain the purpose of enhancing Hazen's stochastic tree model; then it goes through the
enhanced model specifications, model updating using Weibull accelerated failure time
model, and ends with a conclusion section. In the second part of the chapter, nine main
sections describe our design of the simulation model that extends the use of the stochastic
tree, details of how one uses the simulator in conjunction with MAO theory, the
application of statistical ranking and selection, R&S, procedures to select the best
medical intervention configuration of multiple possible configurations. Chapter4-Resultsillustrates examples for the application of the analytical and the simulation models, and
discusses sensitivity analysis on models outputs; and finally it displays the advantages of
our models.
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CHAPTER II

LITERA TURE REVIEW

2.1 BACKGROUND
Reviewing the most relevant methods and techniques related to decision analyses
that can integrate or that append more integration for medical intervention in recurring
diseases/injuries/disorders would be beneficial for the person who is interested in medical
decision making application.
Hazen's stochastic tree model based on medical decision tree
methodology with a technique for solving continuous-time Markov cycle trees. But, the
model was restricted to the exponential distribution for health states stay. So, in this
chapter, section 2 to 4, we discuss and explain: decision-stochastic trees and their limits
in section (2), Markov models and their limits in section (3), and survival analysis and its
limits in section (4). In sections 5 to 7, we discuss and explain: Ranking-Selection
procedures in section (5), Multi attribute utility theory in section (6), and finally will
focus, in section (7), on Simulation models and simulation output analysis.
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2.2. DECISION TREE - AND- STOCHASTIC TREE MODELS
2.2.1 Decision Tree: Moore defined a decision tree by: it is a graphical device for
analyzing decision under risk (Moore, 2001). A decision tree is an essential element of
decision analysis under uncertainty (Raiffa, 1968; and Jaafari, 2003). One of the
advantages of decision trees is the ability it offers to structure the decision problem by
mapping out all feasible alternative actions. As such, it is mainly useful for analyzing
complex sequential decisions when uncertainty is resolved at separate, discrete points in
time.

2.2.1.1 Decision Tree Limits: a decision tree is not a complete representation of
"the real world" but rather a simplified and highly stylized model of the most important
components (Allan Detsky, 1997). Decision analysis by traditional decision tree might be
misused by decision makers tending to focus only on the initial decision to accept or
reject the intervention at the cost of subsequent decisions being dependent on it, decision
tree analysis forces decision maker to bring to the interdependences between the initial
decision and subsequent decisions" (Jaafari, 2003). "With events and sequential decisionmaking over extended periods of time, where consequences cannot be defined to cover
the future, in a medical context, a Markov process had been incorporated into a decision
tree to overcome the unmanageable decision tree" (Pliskin 1975). Also, to handle a
continuous nature, there are two main options to handle such a situation: (1) approximate
the continuous outcomes with a Pearson-Tukey approach, or (2) use the technique of
Monte Carlo simulation designed to handle probability distributions of a continuous
nature. (Moore, 2001)
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2.2.2 Stochastic Tree: For enhancing the medical decision methodology, Beck
and Pauker (1983) extended medical decision tree methodology to consider discrete-time
Markov process-based models; which is helpful when the timing of a treatment is a
critical variable. Recently, Hazen (1992, 93, 96, 98, & 2002) has developed stochastic
trees as a technique for solving continuous-time Markov cycle trees.
Hazen et aI, 1992-to-2002, in the medical decision making field, has developed an
approach that combines features of continuous-time Markov chains with those of
decision trees and that enable time to be modeled as a range where health state transitions
can occur at any instant. "It can also accommodate patients' preferences regarding risk
and quality of life. The stochastic tree concerns itself with the recursive evaluation of
utility function, that it is the calculation of an expected utility measure using iterative
methods (CYCLIC) similar to the method of successive approximations (value iteration)
in the stochastic Dynamic Programming".
2.2.2.1 Stochastic Tree Limits: the stay in any health state is restricted to lowdimensional preference summary (e.g. memory less) for the recursive computations and
to fit with the Markov process property. So, Hazen's stochastic tree model was created
with respect to exponential distribution only; nevertheless, there are other survival data
should be represented in different sojourn (survival models) distributions, such as
Weibull distribution, Gamma distribution, Log-Logistic distribution, Log-Normal
distribution, Coxian, Quadratic, and Bathtub distribution that could be used (Collett,
1999),
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2.3. MARKOV MODELS
Markov models provide a solution to the problem of modeling the natural history
of chronic disease. Their simplicity, computational ease, and broad applicability to many
clinical- and health-related situations make Markov models more attractive than other
more complicated, modes of analysis. The Markov model assumes that the future is
independent of the past given the present. When using Markov the random variable is
indexed in time, which can be either discrete or continuous. Many random events are
affected by what has happened before.
Decision trees often include Markov models to calculate final outcomes or simply
to collapse a bushy branch into one that is more manageable. The Markov model
simplifies decision trees by defining a series of transition probabilities between health
states. These probabilities define the progress of patients through the model.

2.3.1 Classes of Markov Models: There are two broad classes of Markov
models, Markov chains & Markov processes, defined by the determinants of the state
transition probabilities. Markov chains contain constant transition probabilities, whereas
Markov processes have time-dependent transition probabilities. Markov chains are easy
to use and compute in cases where the disease has a short time horizon, because of the
probability restriction; however, with more chronic conditions, the chance of moving
between health states increases with age. Aging increases the risk of transition from a
healthy state to one of sickness, thereby violating the constant state-transition probability
assumption of Markov chains. Markov processes are used to model disease over longer
time periods.
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Behaving similar to the pure Markov model there is the semi-Markov process
model. It is a probabilistic model useful in analyzing complex dynamical systems.
However, with semi-Markov models, the transition rates in a particular state depend on
the time already spent in that state (sojourn time) but that they do not depend on the path
by which the present state was reached. Thus transition distributions in the semi-Markov
process can be non-exponential. The semi-Markov theory involves the concepts of state
and state transition. The most important statistics of the semi-Markov process are the
interval transition probabilities.
Markov processes are useful in representing events where the risk or frequency of
events varies over time. Markov models and Markov chain theory have been applied to a
variety of areas in science and medicine (Hazen literature group, 1992).

2.3.1.1 Markov Models Limits: While conceptually and graphically welldesigned for representing event probabilities with repetitive chances, Markov models
inherently are limited by the Markov property restriction and other assumptions placed on
the transition probabilities. Recall that in the Markov model, the current state of health is
the only information used to predict state transition probabilities. The Markov model has
no memory of past events. This assumption often is violated in clinical situations, where
most clinicians use past information to guide treatment decision making.

2.3.3 Markov Decision Process: a Markov Decision Process (MDP) is just like a
Markov Chain, except the transition matrix depends on the action taken by the decision
maker (agent) at each time step. The agent receives a reward, which depends on the
action and the state. The goal is to find a function, called a policy, which specifies which
action to take in each state, so as to maximize some function of the sequence of rewards.
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One can formalize this in terms of Bellman's equation, which can be solved using policy
iteration. (Feinberg, 2002)
Markov decision process is a mathematical representation of a sequential decision
making problem in which: A system evolves through time. A decision maker controls it
by taking actions at pre-specified points of time. Actions acquire immediate costs or
accumulate immediate rewards and affect the subsequent system state. A MDP is used to
identify a policy that maximizes the expected utility/reward.
2.3.3.1 Markov Decision Process limits: the theory of MDP studies sequential
optimization of discrete time stochastic systems. The basic objective of MDP is a
discrete-time stochastic system whose transition mechanism can be controlled over time.
The concept of dynamic programming, which is very important for MDPs, was
systematically studied by Bellman in many publications; this concept has been used by
several authors to approach various problems (see Feinberg, 2002).
The dynamic programming principle in its classical form can be applied only to
problems with an appropriate single objective function. For some objective functions or
when the goal is to optimize one objective function under constraints on other criteria, the
problem usually cannot be solved directly by dynamic programming. Convex analysis
methods (Eugene, 2002, chapter 11), including linear and convex programming in finite
and infinite dimensional spaces are usually more natural in these situations.
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2.4 SURVIVAL ANALYSES
Disease progression and its effect on survival follow a distribution related to age.
More generally, systems or events that "decay" over time can be modeled using a
survival or hazard function (Collett, 1999). Survival analysis and the hazard function are
useful methods to model treatment effectiveness and program costs. The hazard function
relates survival probabilities to survival times, to treatment costs, or to any other related
factor.
In clinical trials, treatment efficacy often is compared to a placebo or control
group. A hazard function for the treatment group and control group is estimated to
determine the total effectiveness of the intervention and the placebo. The difference
(positive or negative) between the hazard functions is the benefit or cost of the treatment.
Mathematically, effectiveness is measured by the area under the distribution curve or by
taking the integral of the hazard function.

2.4.1 Survival Analyses Limits: survival models often are used in clinical
decision making, under uncertain conditions, to estimate life expectancies. Kuntz and
Weinstein outlined two types of life expectancy biases that may arise in clinical decision
modeling: misestimating bias and misspecification bias (Clarke 2004). Both biases
potentially can limit the accuracy and validity of any conclusions drawn from a predictive
model for survival. Misestimating bias arises because the expected value of a function is
not equal to the function itself. For linear functions, the expected value of the function
equals the function; however, for nonlinear functions, such as life expectancies and
hazard functions, this is not true.
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For most clinical situations, nonlinear functions do not adequately capture the
relationship between survival time and life expectancies introducing miss-estimation bias
into the model (Kuntz, 1995). Misspecification bias occurs when specifying the function
to represent survival outcomes based on the patient's disease and treatment history. There
are a number of parametric survival models available to the decision maker, including the
Weibull, Makeham-Gomperz, and exponential models. Life expectancies are calculated
from the area underneath the survival distribution. When survival distribution does not
reflect the patient's conditional survival probability accurately, the life expectancy
estimates derived from the distribution will be inherently biased (Collett, 1999, and
Kuntz, 1995).
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2.5 MULTI-COMPARISON and RANKING-SELECTION PROCEDURES
Recent research has shown that multi-comparison procedures can be
combined with ranking and selection procedures (R&S) for a variety of problems
including the manufacturing, medical, and polling examples outlined above (see Nelson
2001). Ranking and selection procedures are statistical methods designed to find the
"best" system from a collection of competing alternatives (Nelson 1998 and 2003).

2.5.1 Different Classes of Screening, Ranking-Selection Procedures:
R&S procedures have been expanded over the last 22 years. Kim and Nelson,
(2003), pages 110 and 111, stated four different classes of comparison problems, utilizing
R&S, which arise in simulation studies. However; we consider that there are six different
classes of comparison problems, mainly they are:
1. Selecting the best system(s), of k systems, which has the largest or smallest

expected performance measure; there are many procedures have been developed
(see Bechhofer 1995, Kim-Nelson 2001, and (Nelson-Miler 1995). For example,
Nelson and Miler have developed a Multiple comparison procedure (MCP)
combined with the R&S procedure of Rinott (1978). Rinott procedure is one of
the frequently used procedures in R&S. Rinott+MCP utilize a common random
number to decrease the variance and to reduce the number of observations
required to make a correct selection. (Besides selecting the best system among K,
k ~2, select a subset of size m containing the best of K, & select the m best of K).
2. Comparing all alternatives against a standard (comparison with a standard). The
goal of comparison with a standard is to find systems whose expected
performance measures are larger (smaller) than a standard and, if there are any, to
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find the one with the largest (smallest) expected performance. For this type of
problem, each alternative needs to be compared to the standard as well as other
alternative systems. (see Nelson 1998, Nelson 2001, and Kim (2003).
3. Selecting the system with the largest probability of actually being the best
performer (multinomial selection). When we are interested in the actual value of
performance measure and not the expected value of performance, then the goal is
to select the design associated with the largest probability. (see Nelson 1998, and
Bechhofer 1995).
4.

Selecting the system with the largest probability of success (Bernoulli selection).

In Bernoulli selection problems, the basic output from each system on each
replication is either one ("success") or zero ("fail") and the best is defined as the
system with the largest probability of success. See chapter 7 of Bechhofer et aI,
(1995), for a inclusive reference.
5. A fifth approach is, by Morrice et aI, 1998, to convert multiple performance
measures to a scalar performance measure using multiple attribute utility (MAU)
theory. MAU theory can be used instead of a costing approach when good cost
data are not available. Alternatively, MAU theory can be used to beautify costing
information that is considered to be incomplete/ indefinable. This approach
combines multiple attribute utility theory with statistical R&S using the
indifference zone approach. And its goal is to select the best project configuration
from a set of K configurations when project performance is measured over
multiple performance measures. (Morrice 1998)
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6. There is another formulation; the Bayesian approach: Instead of providing a
probability of correct selection, (PCS), guarantee, Bayesian approaches attempt to
allocate a finite data resources to maximize the posterior PCS of the selected
system. (Chen 2000 and Chick 2001) are two recent references.
A good procedure is one that delivers the desired the probability of correct
selection (PCS) efficiently (with minimal simulated data) and is robust to its underlying
assumptions. The "best" mainly means the maximum/minimum expected-value (or
probability) of performance, such as expected cost. R&S origins to two papers:
"Bechhofer (1954) established the indifference-zone formulation, (IZ), while Gupta
(1956, 65) is credited with the subset selection formulation of the problem, and both were
developed for the inference provided by hypothesis tests for the homogeneity of the k
population parameters, usually means." (Kim 2(03)
2.5.2 Multiple Comparisons: in statistics, there are different approaches of
comparison such pair-wise comparisons. Case of comparing two alternative systems and
case of comparison with a standard are two examples. Moreover, there is what called
multiple comparisons, and multiple tests; a researcher would better to make a distinction
between them.
Our work, from this point of view, combines multiple comparisons, and rankingselection procedures. Multiple-comparison procedures (MCPs) treat the comparison
problem as an inference problem on the performance parameters of interest. MCPs
account for the error that arises when making simultaneous inferences about differences
in performance among the systems. Usually, MCPs report to the user simultaneous
confidence intervals for the differences.
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Multiple Comparisons Procedure approaches the comparison problem by
providing simultaneous confidence intervals on selected differences among the systems'
parameters. Hsu, 1996, is good reference. MCP forms simultaneous confidence intervals
for {fli- max !1s), where #i and i= 1,2 .. .. k, the difference between each system and the
best of the rest. There are other procedures that combine more than approach in one. For
example, Nelson (2001), developed what is called NSGS procedure combines a Guptalike subset-selection procedure and a Bechhofer-like ranking procedure. The NSGS is
appropriate for terminating simulations or for steady-state simulations when multiple
replications are employed.

2.5.3 Multiple Comparisons and Multiple Tests: To make more than one
decision in a statistically valid way, multiple inferences are involved. There are numerous
alternative solutions for multiple inference problems---"some are very good, some
perform reasonably well, and some are of questionable value. The wide variety of
methods that are available can make the choice of technique difficult" Westfall et al.
(1999). There are various methods, along with their pitfalls and advantages. There are
various applications in many areas, including business, medicine, sociology, and
engmeenng.
The proper choice of a multiple inference procedure depends upon researcher
inference objectives and data structure. In some statistical software there are procedures
for such inferences (e.g. in such as SAS: the GLM, MIXED, and MULTTEST); in
several types of problems, they are not particularly well accommodated, and so to fill this
gap, there waslis a need for a set of macros and programs. Westfall et al. (1999)
introduces some of the new methods, SAS-macros, and capabilities for multiple
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comparisons, allow researchers to carry out multiple inferences in most applications of
practical interest.

"Multiple comparisons" usually refers to the comparison of mean values from an
experiment with multiple groups. For displays, labeled A, B, and C, using the data to
compare display A with display B, A with C, and B with C. This is the classic "multiple
comparisons" application; and there is a variety of methods for such analyses (e.g.,
Tukey's method for comparing means in the SAS PROC GLM for example).

" Multiple testing" on the other hand, concerns a broader class of applications. For
example, a clinical trial designed to assess "efficacy" of a pharmaceutical compound
might be considered "efficacious" if it reduces fever, or if it speeds recovery time, or if it
reduces some pain. Here, there are three tests-a comparison of active compound with
placebo for each of the three outcomes. This is an example of "multiple testing."
The distinction between multiple comparisons and multiple tests is that, with
multiple comparisons, the researcher typically compares mean values of the same

measurement, while with multiple testing, the researcher considers multiple
measurements.
Formalism: Technically, the problem of multiple comparisons-multiple testing
problem can be described as the potential increase in Type I error that occurs when
statistical tests are used repeatedly: If n independent comparisons are performed, the
experiment-wide significance level 0. (alpha) is given by

1 - (1 -

G per compar:iso.n.)n

1

and it increases as the number of comparisons increases.
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In order to retain the same overall rate of false positives (rather than a higher rate)
in a test involving more than one comparison, the standards for each comparison must be
more stringent. Intuitively, reducing the size of the allowable error (alpha) for each
comparison by the number of comparisons will result in an overall alpha which does not
exceed the desired limit, and this can be mathematically proved to be true. For instance,
to obtain the usual alpha of 0.05 with ten comparisons requires an alpha of 0.005 for each
comparison to result in an overall alpha which does not exceed 0.05.
There has been a great deal of attention paid to developing better techniques for
multiple comparisons, such that the overall rate of false positives can be maintained
without inflating the rate of false negatives unnecessarily. Such methods can be divided
into general categories (Benjamini 1995):
•

Methods where total alpha can be proved to never exceed 0.05 (or other chosen
value) under any conditions. These methods provide "strong" control against
Type I error, in all conditions including partially correct null hypothesis.

•

Methods where total alpha can be proved not to exceed 0.05 except under certain
defined conditions.

•

Methods which rely on an omnibus or compilation test before proceeding to
multiple comparisons. Typically these methods require a significant
ANOV AlTukey range test before proceeding to multiple comparisons. These
methods have "weak" control of Type I error

•

Empirical methods, which control the proportion of Type I errors, utilizing
correlation and distribution characteristics of the observed data.
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The advent of computerized resampling methods, such as Bootstrapping and
Monte Carlo simulation, has given rise to many techniques in the latter category. In some
cases where exhaustive permutation resampling is performed, these tests provide exact,
strong control of Type I error rates; in other cases, such as bootstrap sampling, they
provide only approximate control.
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2.6 MULTI ATTRIBUTES UTILITY THEORY (MAU)
MAU theory is one of the main analytical tools in the field of decision analysis.
Simply, decision analysis is an approach to the solution of problems that are complex to
solve informally. A MAU analysis of alternatives (in our research, treatment patterns)
helps to identify the alternative that performs well on a majority of performance
measures. The MAU methodology for the evaluation of a set of alternatives typically
starts with (a) identifying of alternatives and measures, (b) estimating of the performance
of the alternatives with respect to the measures, (c) developing utilities-weights for the
measures, and (d) evaluating of the alternatives.
The alternatives and the performance measures form a matrix in which each row
corresponds to an alternative and each column represents a measure. The cells of the
matrix contain estimates of the performance of each alternative on each of the measures.
Next step generates a single attribute utility function over each measure that is scaled
from 0 to 1, a weight for each measure, and a multiple attribute utility function derived
from the single attribute utility functions and the weights. There is more than one method
for assigning weights to the performance measures (Schoemaker 1982). A single attribute
utility function is a scoring function that maps a performance measure from its range of
possible values to [0, 1].
Regular forms of this function include concave, convex, linear, and "s" shaped
for a mixture of the convex and concave functions. One known form for single attribute
utility function is
U(x)

= G-H e- (YfJ) ..... (1)
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The quantities G, H, and T are parameters that set by the decision maker (in medical
literature, it is common to set G=H= 1 for patients, as patients are risk avoider.
In the analysis utility theory involves gathering the measures into a "UnifiedMeasure" of the desirability of each alternative. Utility theory provides the basis for the
appropriate approach to combined the apparently unlike measures.
If the decision maker's preferences are consistent with some special independence

conditions, then a multiple attribute utility model

U

(Xl,

x2 ,... , x n ), where xi represents

the level of performance on measure i, can be decomposed into an additive,
multiplicative, or other well structured forms that simplify assessment. An additive
multiple attribute utility model can be represented as follows:

IIh·l • '\'1"'"

"
xJ == III'JI;{XJ

(2)

,:1

Where

o to

Ui(.)

is a single attribute utility function over measure i that is scaled from

1, Wi is the weight for measure i and sum of Wi

= 1, I = 1,2, ... n.

If the decision maker's preference structure is not consistent with the additive model (2),

then the following multiplicative model may be used, which is based on a weaker
independence condition:
I +kU(.\·I'.\·1 .. ·· ..\·n)=

"
nIl
tkk,lI (\H
j

(3)

;=1

Where uiC.) is also a single attribute utility function scaled from 0 to 1, the ki 's are
positive scaling constants satisfying 0 ::::; k;::::; 1 , and k is an additional scaling constant that
characterizes the interaction effect of different measures on preference. Methods for
determining the value k can be found in Keeney and Raiffa, 1976. As a special case when
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sum of ki = 1, the multiplicative model (3) reduces to the additive model (2) (Keeney and
Raiffa, 1976).

2.7 SIMULATION MODELS
David Kelton et aI, (Kelton 2001), defined simulation as: "a broad collection of
methods and applications to mimic the behavior of real systems, usually on a computer
with suitable software". Jerry Banks et aI, (Banks 1995), had defined simulation as "the
imitation of the operation of a real-world process or system over time".

2.7.1 Simulation models
•

Monte Carlo Simulation: Monte Carlo models are prearranged likewise to Markov
models, but their outcome evaluations are determined by repeated iterations of the
model based on random assignment of model parameter. Monte Carlo simulation
(traditional simulation) techniques use repeated random sampling from the
probability distributions assigned to each of the crucial primary variables the
patients flow of a treatment to arrive at output probability distribution for a given
medication strategy. Monte Carlo simulation is a forward-looking technique based
on a predetermined operating strategy; as such, it may be an appropriate model for
path-dependent or history-dependent problems. (Jaafari, 2003)

•

Process Simulation: "process simulation permits investigation of an intervention
concept to generate the expected units of output. It also permits investigation of
the interrelationships among constituent parts of a medication study. Process
simulation can be a prior to pilot medical-project operation." (Jaafari, 2003)
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Process Simulation should run before startup or charge of the actual arrangement
or, with the use of a spare offline system, anytime.
•

There is what is called Nevada Simulation; NEVADA Simulation, developed by
David 1. Bryg, (1992); it is very competitive compared to Monte Carlo simulation
in terms of accuracy and speed. NEVADA Simulation employs numerical
integration to calculate functions of random variables. This technique contrasts to
Monte Carlo simulation, which uses sampling to calculate functions of random
variables.

In our work, we utilize Monte Carlo simulation techniques.
Simulation has advantages, (Jerry Banks, et al 1996): First, simulation can be a

method of last alternative for problems that are mathematically intractable by any other
techniques. Second, even for problems that are mathematically tractable, simulation can
often provide a higher level of detail than can other techniques. Third, simulation can
sometimes provide (approximate) answers at a smaller cost (or effort) to some problems
which are fully tractable mathematically but whose solution may be cumbersome and
time consuming.
Other advantages of simulation include that it permits modification or design of
medical intervention systems by trial and error, allows for easy exploration of the

system's sensitivity to changes in the input parameters, and provides a highly controllable
environment for experiments. Simulation can be valuable to the operations researcher as a
means of testing the applicability and validity of mathematical models and expressions.

2.7.1 Simulation Limits, the disadvantages of simulation as a technique are also
primarily due to the fact that simulation is basically an experimental approach to solving
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problems (Jerry Banks, et al 1996). As a result it is difficult to develop cause-and-effect
relationships through simulation, especially when the system under consideration
requires the specification of many input parameters and involves complex interactions.
Finally, as with all experimental results (and, actually, more so) the statistical analysis of
simulation results is difficult. What is the effect of the starting conditions of the
simulation on the final results? What is the statistical confidence that can be attached to
the results?
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2.7.3 Output analysis for Terminating Simulations for the Fixed-Sample-size
Consider output performance measure X, e.g., the average QAL Y for a patient in
the single-treatment system. Let Xj be the value of the performance measure in the jth
independent simulation replication, j= 1,2, ... ,n. Xj are lID observations of the performance
measure
Estimating the mean:
The fixed-sample-size procedure for m=E(X)

Choose n and make Independen t Replicatio ns of the simulation

1-

a confidence interval for f.1 is
+
~
X (n) - t n- I ,I-aI2 ~-;;-'
_
where X (n)

1

=-

n

Il

LXi'
i=1

n

L(X i

and S 2 (n) =

-

X(n))2

-'--i=--=-I_ _ _ _ __

n -1
Coverage: t-interval assumes normality of X I, X2, ... Xn. Robustness depends on the
sample size and on the simulation model. Effect of departures from normality may be
assessed with comparison to known results.

Obtaining specified error: Absolute error

f3 = IX (n) -

ILl

We make sufficiently many runs so that the half-length of the I-a confidence interval is
equal to or less than ~
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Initially, make n runs
I-a

~

t'(n)
P X(n)-t n _ I,I_aI2 t'(n)
n '5:.J1'5:.X(n)+t
n
n _ I,I_aI2

=

p IX(n) -

'5:.

P~X(n)-J1I'5:.f3)

J

pi t"_I'I-a/2t'~n) J
S;

Assume the variance estimate will not change with increasing n,
The total number of runs n: required to obtain error of at most f3 is

~

. {.1 >
< f3}
na* -- mIn
- n.. ti-I,I-aI2~~-

Obtaining specified error: Relative error

r =IX (n) - 1l1/11l1

We make sufficiently many runs so that the half-length of the I-a confidence
interval, divided by the estimate of the mean, is equal to or less than y
A sequential procedure

Choose an initial number of replicatio ns no

~

2 and define the confidence

interval half - length as
J(n, a)

= t n- I,I-aI2 t'(n)
n

O.

Make no replicatio ns and set n = no

1.

Compute X(n) and J(n,a) using X I ,X 2 "",X n

2.

If o(n, a)/IX(n)1 '5:. r', use X(n) as estimate of f.1 and stop.
The 1- a confidence interval for f.1 is [X(n) - o(n, a), X(n) + o(n, a)]
Otherwise set n = n + 1 and go to step 1.

Recommendations:
(1) no is recommended to be larger than or equal to 10
(2) rno is recommended to be less than or equal to 0.15
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2.7.4 Output Analysis for Terminating Simulations When n can be determined
When n can be determined many methods may be applied to select best system,
such as multiple comparison, ranking and selection, interactive analysis, etc.
Example (1) (Goldsman, Nelson 1998): suppose that Airline-Reservation System,
Consider k=4 different systems; and the objective is to maximize E[Time To Failure].
From experience, E[TTF] roughly 100,000 minutes for all four systems; and the
indifference zone is 3000 minutes.
•

Solution by Interactive Analysis: an estimation approach: It considers 4 point
estimators for E[TTF]'s; and estimates their standard errors; the goal is a vague,
but well-founded, sense of confidence in the selected system; IA here contains the
explicit confidence-interval judgment.
The Method: m=number of micro-replication, b=number of macroreplication; n=bm; the point estimator for fli , i=1,2,3,4 (the E[TTF] of

system i) :

_ Ib_ Ibm
YI =b 'Yo
£. IJ =- "
£. Y
£. 'IJl
j=l
n j=ll=l
With associated sample variance of the macro-replication estimators :

sei

-

-

S.I

.fb

The Assumptions: People choose a arbitrarily and small b & a can lead to large tvalues; Choose 1O<b<30 is often wise (Goldsman, Nelson, 1998); lfthe value of
b is reasonably large, the effects of sequential sampling are negligible.
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Initial run is designed just to gain a sense of the magnitude of the required
production experiment in terms of time per replication and number of replications
System: standard error (se) =21000, and b=m=5; indifference value=3000; so the
(se) will need to drop to at most 1500; this means that the "worst -case" is 5000
replications.

•

Solution by Ranking & Selection: it is to select the best system from a set of
competing systems. The probability of a correct selection will be at least some
user-specified value. For example, when variances are unknown two-stage R&S
procedure such as Dudewicz-Dalal, (1997), and Rinott's (1978) procedure
required; the two stages of sampling guaranteed PCS. The normal means
procedure of Rinott, (1978):

The Method: Ordering
If

U[kJ - u[k-lJ

U[I]::S; U[2]

::s; .•. ::s;

U[k]

;

the two best

U[kj,U[k-lj

is very small, less than 8>0; it wouldn't matter which one we

chose as best (8=3000). We take p* = 0.9 in our example; P(CS) 2: P*=0.9
The first -stage sample means and sample variances
h

f;(l) = !

y

---.!L
j=1 bo

s.2 =
I

t/J;j- -

D(I) 2

Ii

j=1

)

(4J -1)

The sample variances are used to determine the number of macro-replications
which must be taken in the second stage

(a) h is a function in the number of replications n, the number of systems k, and 6.
To find h value, named g, see Bechhofer, (1995), page 62.
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(b) So b i - bo

additional observations must be taken. Finally we get grand
-

_

means Y i =

bi

y.

L ....!L,i
= 1,2, ... , k and select the system with largest };
b
j =l

I

i

(c) The macro-replication estimators, y~
y.
y
r1' 12 , ••. , Ib,

from the ith system are

assumed to be i.i.d. with expectation. If the number of micro-replications m is
large enough the Central Limit Theorem (CLT) yields approximate normality for
the macro-replication estimators. For sampling bo=20, intend to be used as the
first stage:

Table 1: Pilot experiment on Ranking & Selection
1

2

4

3

108286 107686 96167.7 89747.9
29157.3 24289.9 25319.5 20810.8
6519.8

5431.4

5661.6

4653.4

699

485

527

356

Table 2: Pilot experiment on Ranking & Selection Result
1

2

3

4

110816.5 106411.8 99093.1 86568.9
872

1046.5

894.2

985.8

Final Results: For the case k=4, P*=0.9; and h=2.720 (Bechhofer, (1995), page 62);
for system 2, we needed to take 465 additional macro-replications in stage 2. We are
at least 90% sure that we have made the correct selection (u(l) -
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U(2)

>&=3000)

Output analysis for terminating simulations:
Solution by Multiple comparisons: There is no distinction between micro and
macro-replication

y.IJ

=u. + B··
I

Bij

IJ

are iid normal

(0,(12)

- - tr,- - tt

(~-m~x~ -ds 1*,

i

n

(~-m~x~ +ds -

n

l~

is pooledestimatoroJ (12

d

=dl-a,k(n-l),k

x- =min{O,x} , x+ = max {O, x}

Lower endpoint is 0, then system i is the best system
Upper endpoint is 0, then system i is bad system

Assumption: Data from one-way analysis of variance; use different random
number seed to generate sample, so the relationships between samples are
independent. Sample from normal and common variance

Y ij - normal

distributi

on VAR (Yij) =

a

2 \;/

i, j

Pilot experiment (Batch mean)
Because n replications need to be large that samples may be normally distributed, so
use batch mean method to generate sample.
U sing batch mean will tend to form the normal distribution, but the drawback is the
lose of degree of freedom

Yil 'Yi2 ,... , Yin become to batch mean formal bim i = n
1 ~
Yi/ = - L ~,(l-l)mi+ j
m i j=l
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For n=200, b=40 and m=5

Table 3
A Pilot Experiment on MCP
Lower limit

Y; -max Y

Upper limit

-11349

7091

25530

-31242

-12802

5638

-25530

-7091.

11349

-36172

-17732

708

{",i

Since all system contained 0 no system could be declared to be the best. S=92449,
d=2.078, n=8100 for final result.
n;?:: (

J2dl - a ,k(n-l),k CY )2

Let half interval of CI:::; 8

£5
Using Bartlett's test for equality variance, the result is different, so set b l =b2=b3=100,
and b4 =150, let variance is same.

Table 4
Final Result on a Pilot Experiment on MCP

r: -maxY

Upper limit

o

5288

8284

-8284

-5822

o

-12747

-9751

o

-25409

-22675

o

Lower limit

Zot:i

System 1 is the best.
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Table 5: Comparison Methods' Differences and Similarities
Micro

Marco

Method

CI

Stage

No

One

Assumption

replication replication
Sample from
Yes

Yes

iid normal
Sample from
Yes

Yes

No

Two
iid normal
iid normal

No distinguish

Yes

Two Common variance
but will check it.

It is difficult to have a common variance in n systems/models, so R&S have an advantage

on MCP. R&S can handle comparison with not common variance.
Table 6: Comparison Methods Advantages and Disadvantages
Disadvantage

Advantage
oncompetitive system are eliminated quickly

of precise confidence
better system is not
more observations is

P{CS}2:P*

provides inference about not only the best
ystem, but also relationships among all the
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distributional

We will use Rinott's (1978), it used when variances are unknown; it is two-stage
R&S procedure; the two stages of sampling guaranteed PCS. Rinott's (1978) procedure:
Satage I: take a random sample of no observation from each system i.
Stage II: calculate ~ and variance S2 for each system; take additional observation from
each system I where,

T

"',
,

\

I.

hS
21}
r
max { I ( T) I
i

110,

Where h=h (k, 1- a, no) is a constant determined by k, the number of systems being
compared; I-a, the desired confidence level; and no, the number of first stage
observations used to produce the variance estimator, (Si)2. The constant h increases in k,
and decreases in a and no. The experiment design factor that is under our control is no,
and it is recommended to be at least 20. Calculate new ~ and variance S2 for each system
based on the combination results of stage I, and II. Select the treatment that has max Jl to
be the best system.
Our simulation model is not a steady-state simulation model; it is a terminating
simulation. We assume that performance measures have no correlations, i.e. we suppose
that the performance measures are utility independent; however, our model can handle
performance measures which are utility dependent or utility independent.
Nelson, et al. (2001), developed a procedure related to Rinott called NSGS
procedure, it is appropriate when there are large number of replications, and for
terminating simulations or for steady-state simulations when multiple replications are
employed. The NSGS procedure requires that the output data from each system are i.i.d.
normal, and that outputs across systems are independent, which leaves out CRN. Nelson
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et al. (2001) showed that the NGSG procedure can handle a relatively large number of
systems because the first-stage screening is pretty tight. Nelson et al. (2001) provide a
revised version of the NGSG procedure, the Group-Screening procedure, in which one
can avoid simulating all the systems simultaneously. But, in medical intervention, there is
not large number of systems to be tested for specific recurrent disease.
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CHAPTER III
METHODS

An Enhancement of the Stochastic Tree Model for Medical Decision
Making (Model I)

~odeII.Background

While conventional decision models are an attractive way in which to model
problems under uncertainty, they cannot investigate disorders that are recurring in nature.
Stochastic tree models were developed to deal with cyclic disorders. Some stochastic tree
models were developed to deal with recurrent diseases and to utilize a specific probability
distribution for health states sojourn (see Hazen 1992-2001). However, some disorders
are best represented by probability distributions other than that allowed by stochastic
trees. Furthermore, such stochastic tree models cannot correct and consider boundary
differences of the experimental treatment circumstances and conditions and the standard
treatment circumstances and conditions. In this chapter we utilize the Weibull
Accelerated Failure Time model (W AFT) to extend the stochastic tree modeling
technique. This new technique is a novel way in which to analyze cyclic disorders and
recurrent diseases.
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Model I. Introduction
Decision trees represent a functional way in which to analyze problems under
uncertainty and provide a mechanism to analyze decisions under risk (Detsky, 1996-97).
Conventional decision trees examine complex issues composed of discrete sequential
events; such as, undergoing tests, receiving the tests results, and deciding on the optimal
medical management. Conventional decision trees do not completely represent "the real
world" since they cannot investigate disorders that are cyclic in nature (Jaafari, 2003). As
a result, researchers have developed methodologies, via Markov processes, allowing for
the examination of cyclic disorders. For example, Hazen developed a stochastic tree
model, combining features of continuous-time Markov chains with those of conventional
decision trees in order to analyze cyclic disorders (Hazen, 1992-2001).
Hazen's stochastic tree model allows health state transitions to occur at any
instant. In Hazen's stochastic tree technique, the time spent in any health state is
restricted to a low-dimensional preference summary (e.g. memory less, Markov, and
semi-Markov) for ease utility recursive computations. The notation of preference
summary: memory less is an updatable preference summary in which conditional
preference depends not at all on the past; the Markov summary is conditional preference
depends only on the most recent state; the semi-Markov summary is conditional
preference depends on the most recent state and its stay time. Hazen's stochastic tree
modeling technique can only utilize an exponential distribution for health state sojourn.
Noticeably, some re current diseases can be best represented by distributions such as
Weibull distribution, Gamma distribution, Log-Logistic distribution, Log-Normal
distribution, Coxian, and Quadratic distribution (Collett, 1999). In addition, the stochastic
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tree modeling technique does not have a method to correct differences between
experimental conditions and the corresponding conditions of a current treatment.
Quality-adjusted life years (QALY s) are the measure of health benefit to an
individual that reflects the gain in expected utility for the individual. QALY s can be used
to represent utility only if individuals are willing to trade off years of life in a given
health state for fewer years at an ideal health state at a constant rate, irrespective of the
number of years spent in the state. In addition, it would be beneficial if these
methodologies integrate an individual's specific health conditions (e.g. smoking history,
body mass index).
In this part of our study, we extend Hazen's stochastic modeling technique, which
incorporates the memory-less exponential distribution by utilizing the Weibull
Accelerated Failure Time model (WAFT). The WAFT model is memory-less when
Wei bull 's shape parameter equals to one, but also integrates specific health conditions at
the individual level. This new technique may not only provide a novel way in which to
study QALY s, it may also provide a novel way in which to analyze recurrent diseases.

39

Model I. Specifications and Design
Model I is an analytical model: An Enhancement of Hazen's Stochastic Tree
Model Using Weibull Accelerated Failure Time Model for Medical Decision Making in

Recurrent Diseases/Injuries Specification
Use of Survival Analysis: Systems that "decay" over time can be modeled using a
survival or hazard function. As a result survival analysis is a useful method in which to
model treatment effectiveness and cost. In clinical trials, treatment efficacy often is
compared between a placebo and control group. A hazard function for the treatment
group and the control group can be estimated to determine the total effectiveness of both
the intervention and the placebo. The difference between the respective hazard functions
represents the benefit or loss associated with the treatment.

Survivor and Hazard Functions: The survival time of a particular individual, t,
can be regarded as the value of the random variable T representing survival time. Thus,
the different values that T can take correspond to a probability distribution function,f(t).
The distribution function of T is then given by:
t

f

F(t) = P(T < t) = f(t)du
o
The survivor function S (t) is defined as the probability that the survival time is
greater than or equal to t, that is,

Set) = P(T ~ t) = 1- F(t)
For recllirring sickness or weakness due to illness, the morbidity ratio as a function
of that recurrence can be regarded as a survivor function for use in survival analysis. The
hazard function is then defined as the probability that a patient's sickness/weakness level
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will reach some defined failure criterion (a morbidity ratio reduction of m% at time t,
conditional on the patient having survived to time t). Thus the hazard function is the
instantaneous harm rate. Hence from (Collett, 1999, page 12),

h (t)

=

lim P (t :s; T

< t + ~ tiT ~ t)
~t

Ot-70

For two events A and B with PCB #0, the conditional probability of A given B can
be expressed as:

P(AI B) = peA n B)

PCB)
Therefore,

P( t

~

T <

t

S:IT)
+ ut
~ t

F(t+~t)-F(t)
= P(t~T<t+M) = -'-------P(T~t)

Set)

Hence,

h (t)

= lim P Ct ~ T
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The derivative of F (t) with respect to t isf(t). Hence, the hazard function h (t)
used in survival analysis is defined as

h (t) = F' (t ) =

s (t)

And,

f

(t) = -

s (t)

~ (In S (t))
dt

d
d
J(t) = h(t) * Set) =[--(InS(t»] * Set) = --Set)
dt
dt
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Weibull Model: the Weibull distribution plays a.central role in the analysis of
survival data. Introduced by Weibull in 1951, in industrial reliability testing, this
distribution is fundamental to the parametric analysis of survival data. Research has
demonstrated that improving health associated with a medical intervention can be most
accurately represented by a survivor function using a Weibull density function (Collett,
1999). The Weibull approach uses a "recursive" approach. That is, harm is updated
throughout a patient's life, with the morbidities/weaknesses in period n adjusted for the
patient's conditions in period n, and accumulated illness harm through period n-l . The
Weibull model provides a better description of the non-linear accumulation of harm of
the sickness levels when compared to traditional linear hypothesis of cumulative harm.
The Weibull density function has the following form

where

(1)

A: (or L) is the scale parameter and y (or G) is the shape parameter; with both parameters
being non-negative. Figure 1 Three different curves of Weibull density function:
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When disease harm progresses, experimental morbidity tests follow a Weibull
distribution with a baseline hazard function of the form

Accelerated Failure Time Model: the accelerated failure time model is a general
model for survival data, in which explanatory variables measured on an individual, are
assumed to act multiplicatively on the time-scale. This means that the models can be
interpreted in terms of the speed of progression of a disease, an interpretation that has
immediate intuitive appeal.
One interpretation of this model is that the lifetime of an individual on a new
treatment is a multiple of the lifetime that the same individual would have experienced
under a standard treatment by a constant. When the phenomenon of concern is death,
values of less than unity correspond to acceleration in the time to death of an individual
assigned to the new treatment. The standard treatment would then be the more suitable in
terms of promoting longer life. Conversely, values of greater than one occur when the
effect of the new treatment prolong life. In these circumstances the new treatment would
be viewed as superior to the standard. The parameter is therefore termed the acceleration
factor.
The effect, due to different boundary conditions, is to increase or decrease the
harm based on each of the patient's conditions. Under this assumption, the probability
that a patient in the experimental group survives beyond time t is the probability that a
patient in the non-experiment survives beyond time ~t, where ~ is an unknown, positive
constant. Thus, the ~ term is analogous to the shift factor, a correction factor applied to
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the patient in the experimental group to obtain the corresponding patient life in the nonexperimental group, and is caused by the differences of boundary conditions between
experimental and non-experimental life.
Now letting SExper (t) and SNon-Exper(t} be the survivor functions for some
experimental treatment and the current standard of care, respectively. Then, the
accelerated failure time model specifies that:

!Exper(t)

=!Nof!_Exper(cDt) -------------(2)

for any value of the survival time t.
Following the relationship between the survivor function Set), probability density
functionf(t) and hazard function h(t), the relationship between the density and hazard

functions can be derived as follows:
The derivative with respect to time of (2) above,

dS

Exper

(t) _ dS

NOll _ Exper

dt

(<I> t )

dt

Then we have
-----------(3 )

According to the definition of the hazard function S

(t)
Exper

We obtain
hExper (t)

= <l> hNollJxper (cDt)

-----------(4)

The parameter <l> must be non-negative; therefore, it is convenient to set cD as an
exponential function.

The Weibull Accelerated Failure Time Model: experiment is extremely
important as a part of the medical intervention design. The information obtained from the
experiment must be applied to predict the effectiveness of a proposed treatment.
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However, it is inefficient and very difficult to make the boundary conditions of the
experimental treatment exactly match those of the standard treatment.
As a consequence, a correction factor, "<1>", is needed to correct for the difference
in boundary conditions. To predict the patient performance, it is important to understand
every feature of the correction factor. It should be noted that the comparison between
original data curves and experiment curves needs to be made under the same test
conditions. These conditions, if not the same, should be as similar as possible to eliminate
potential bias.
Under the assumption, if the health decline process of an experimental treatment
is a Weibull function with scale parameter A and shape parameter y; the hazard function
of the accelerated failure time model for the standard of care can be represented as the
following:

and its survivor function can be defined as
t

S Exper (t) = exp( -

f

hExper (u)du)

= exp( -A<I>YtY)

o
which is a Weibull function with scale parameter A<I>Y and shape parameter y
Having, J(t) = hazardJunction(t}

J(t)

* SurvivaIJunction(t},

then:

=h(t) * Set) = (<I>Y AJ1Y-I) * exp( -A<I>Yt Y) ...... (5)
Setting <Di= exp('L f3j Xja, the Accelerated Failure Time Model (AFTM) is a

general model for survival data, in which explanatory variables Xi measured on an
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individual are assumed to act multiplicatively on the time-scale and therefore affects the
rate at which an individual proceeds along the time axis.
This distribution has both the proportional hazards property and accelerated
failure time property. The advantage of the Weibull Proportional Hazard model is that it
can represent all the various experimental situations with an integrated equation in which
the parameters can be easily estimated with linear regression. The AFT model introduces
a method to correct for the boundary difference between experimental treatments and the
standard of care. The Weibull accelerated failure time model is proposed as a way to
bridge the gap caused by the difference of boundary conditions between medical nonexperiment results and the actual outputs when a new medical intervention applied on
patient.

Stochastic Tree: for enhancing the medical decision methodology, Beck and
Pauker (1983) extended medical decision tree methodology to consider discrete-time
Markov process-based models; which is helpful when the timing of a treatment is a
critical variable. Recently, Hazen (1992, 93, 96, 98, & 2002) has developed stochastic
trees as a technique for solving continuous-time Markov cycle trees.
Hazen et aI, 1992-2002, in the medical decision making field, has developed a an
approach that combines features of continuous-time Markov chains with those of
decision trees and that enable time to be modeled as a range where health state transitions
can occur at any instant. "It can also accommodate patients' preferences regarding risk
and quality of life. The stochastic tree concerns it self with the recursive evaluation of
utility function, that it is the calculation of an expected utility measure using iterative
methods (CYCLIC) similar to the method of successive approximations (value iteration)
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in the stochastic Dynamic Programming".
Stochastic Tree Limits: the stay in any health state is restricted to lowdimensional preference summary (e.g. Markov preference summary) for the recursive
computations and to fit with the Markov process property. So, Hazen's stochastic tree
model was created with respect to exponential distribution only; nevertheless, there are
other survival data should be represented in different sojourn (survival models)
distributions, such as Weibull distribution, Gamma distribution, Log-Logistic
distribution, Log-Normal distribution, Coxian, Quadratic, and Bathtub distribution that
could be used (Collett, 1999).
Stochastic tree rollback: In 1996 Hazen and Pellissier proved that recursive
procedures offer computational advantages for stochastic trees which are large and/or
cyclic. They note that in general, the recursion is too computationally challenging to be
useful, unless there are convenient preference summaries such as the memoryless
property of the exponential distribution (i.e. the computations recursively depend on data
one step only in the past, or depend on data of the first level of health states before the
current state). Stochastic tree rollback is particularly simple with quality-adjusted
duration as the outcome measure (see Hazen-Pellissier, Hazen-Pellissier-Chang 1996).
To represent this, Hazen considered a schematic representation of a stochastic fork:

G

The stochastic fork, above, was formed by competing rates

~i

> 0 at state y, where

~ =Ii ~i and Pi = ~i I ~. Hi is itself a stochastic subtree for which the utility E[u(Hi Iyll)] has

already been calculated.
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E[u(Hi IY~)] is the expected utility (e.g. expected QALY or Cost) associated with the
transition from all the stochastic subtrees Hi to state y, then at G, the E[u(G)]:
v(y)+ L,(,uiE[u(Hi«yK)]
E[u(G)] = (

r(y)

Here,

l

[u(G)]

)

+ ,uL,(PiE[U(H i « yK)]

v(y)

E

+A

=(

r(y)+

A

)

denotes a sojourn of random duration k in health state y. O:S v(y) :S 1 is a quality

of life or a cost value specified to health state y, and 0< r(y) :S 1 is a patient's risk
assessment factor to have treatment; r(y) could be a discount value on the associated cost
of a health state y. r(Y)+A >0, and the symbol « means reached by.

Our Model I Updating on Hazen's Formula
Let u(yljl) is a utility associated at state y. To compute QALY or treatment Cost
(the utility), of a health state y, and according Hazen's formula:
t

u(yExponential) =

f (f v(y)e -r(y)*k dk)
o

0

For the state y sojourn, we replacing the exponential distribution, that Hazen used,
with the WAFT model,f(t) = (<DYAyty-l) exp(-A<DYty). We set y to one in the WAFT
distribution to keep W AFT having e.g. Markov preference summary property for rollback
computations. To compute the utility using J..JJ>e-).</Jt, we have then:
00

u(y WAFT) =

t

f (f v(y )e-r(y)*k dk) * Aq)e -A~*t dt ...... (7)

o

0

48

In this formula, we have WAFT distribution behaving same as the exponential
distribution, plus it has the patient's health condition too.

u(y WAFT) = v(y)] (1- e -r(y)*t) * Af/Je -AI/J*t dt
r(y)

0

1
u(y WAFf ) = v(y )/ ( r(y) + A(J>
) ---------(8)

And r(y) + A(J> >0

Let notation
intercept~,

la 1~ 1) =a + ~t .
~

. represents the affine function with slope

~ and

(see Hazen-Pellissier, 1996, page 794), Supposejand g are functions, let the

symbol j 0 z denote functional composition of j and z, so that if () z)( t)

=j(z( t)).

Fitting with semi-Markovian utility, and according to Hazen-Pellissier, 1996, and
Hazen- Pellissier-Chang, 1996, our recursive formula, under WAFT model, of the
expected utility of G, will be:

v(y)
E[u(G)]

+ ¢L (AiE[u(H i« /

=(

r(y)

v(y)
E [u(G)]=(

+ A¢ L

)]

= (10)

+ A¢)

(piE[u(H i« yK)]

r(y)+A¢

)

r(y)+A(J> >0, and r(y)<>O
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(11)

Subtrees, Hi are reached from state y at competing rates, see figure (2). We also,
supposed that no toll is associated with the transition from state x to state y. Form (10) is
used for a stochastic fork (arcs with rates); and form (11) is used for a chance fork (arcs
with probabilities).

2Jti = f1 =1, if there is chance fork reached by state y with immediate

transition.

Model I. Conclusion of the analytical model: "An Enhancement of Hazen's

Stochastic Tree Model Using Weibull Accelerated Failure Time Model for Medical
Decision Making in Recurrent Diseases/Injuries"
Provided r(y)+Jc([> >0 for formula #8 and #10, in the risk neutral case r(y)=O, we
gain quality adjusted duration U(yWAFT) = v(y)*(Jc([>yi. Focusing on Hazen and Pellissier
model, there was a difficulty with the combination of memoryless utility and exponential
duration that was: u(/xponential) diverges to +00 when rry)+Jc~ O. So only moderately risk
seeker preference

(-A~

r(y)

~

0) may be portrayed (see Hazen and Pellissier, 1996, page

796). Our using of WAFT distribution, will cause U(yWAFT) diverges to +00 when r(y)+Jc([>
~O.

Therefore more risk seeker preference (-A([> ~ r(y)

~

0) may be portrayed when

([» 1.

We introduce an extension to the analytical solution, stochastic tree modeling. In
specific, the Weibull accelerated failure time model was utilized instead of an
exponential distribution. This enhancement may increase the stochastic tree modeling
technique's capabilities, by using different state sojourn distribution and by including a
correct boundary difference between experimental treatment and the standard of care.
However, the stochastic tree model utilizing the Weibull accelerated failure time
model should be restricted to have a memory less property for the rollback computation
with respect to the semi-Markov requirements.
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Multiobjective Simulation-Based Model for Medical Decision Making
On Recurrent Disease Treatment (Model II)

Model II. Introduction
A variety of methodologies have been employed for decision making related to
the treatment of recurrent diseaseslinjury. This model presents an investigation of the use
of simulation on the stochastic tree, with associated techniques related to ranking and
selection, and multi-objectives decision analysis.
The enhanced model, in the first part of this study, was still restricted to have the
preference summary- memory less property- for the rollback computation. Consequently,
it was still limited to specific survival distributions. So, further work was required to add
more capabilities and extension not only for the related limitations on the use of specific
survival distributions, but also to add multi-performance measures approach.
For this second part of this research, we developed a simulation model that
maintains multiple input parameters and multiple performance measures. In our study,
the following research section describes our design of the simulation model that enhances
and extends the use of stochastic tree, the application and details of how we use the
simulator, multiple attribute utility theory, and statistical ranking and selection (R&S) to
select the best medical intervention configuration of K > 1 possible configurations.
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Model II. Background
Many publications are related to stochastic models in medical decision making.
Some researchers concentrate their efforts on medical outcomes and others focus on
minimizing the cost of treatment. Integration and contribution of these can be obtained
and it would be added valuable information.
Traditional decision analysis is used to indicate decisions favoring good outcomes
even if there is risk adjoining the decision. The value of each possible outcome of a
decision, whether measured in costs and benefits or utility, is usually variable. As the
number of treatment options and strategy choices has exploded and the cost of carrying
out research has varied, the best treatment for all clinical situations cannot be determined
by conducting randomized controlled trials only.

Model II. Specifications and Design
Most of the R&S literature focuses on procedures that are designed for scalar
performance measures (Bechhofer, 1995). However, some multivariate results do exist.
Gupta (1979) describes procedures that are based on scalar functions of the mean and
covariance matrix of the multivariate populations. Gupta's procedures reduce the
multivariate performance measure problem to a scalar performance measure problem.
Unlike the procedures described in Gupta, our method does not require the complicated
step of estimating a covariance matrix. As a result, the R&S approaches (i.e. Law and
Kelton, 2000) that we use are simpler to implement and belong to a class of procedures
whose properties are better understood.
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In a medical setting, a different approach is often used: Convert project
performance over multiple measures to a scalar measure using costs. Even though this
type of "costing" or pricing out performance measures has many noticeable advantages, it
has some disadvantages as well. For example, perfect cost data may not be available
because of not enough resources. Moreover, it may be not easy to accurately attach a
dollar value to intangibles (e.g., the quality of life) even if the resources are available.

In our simulation model, we utilize an approach, similar to Morrice et al. (Morrice
2001), to this problem: convert multiple performance measures to a scalar performance
measure using multiple attribute utility (MAU) theory (Keeney and Raiffa 1976). MAU
theory can be used with the costing approach and it can be used instead of a costing
approach when good cost data are not available or when cost is not suitable as a measure
of performance.

In this research, we extend Hazen's stochastic tree using discrete event simulation
modeling, MAU theory, and statistical R&S with indifference-zone approach of Law and
Kelton, (2000), to select the best medical intervention configuration from a set of K
configurations when a medical intervention performance is determined by n performance
measures, n> 1. In our model, we follow the same combination technique of Morrice et al.
(1998,1999) to link R&S procedure with MAU theory.
We developed a simulation model that maintains multiple input parameters and
multiple performance measures. This part of our research describes our design of the
simulation model that enhances and extends the use of stochastic tree, the application and
details of how we use the simulator, multiple attribute utility theory, and statistical
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ranking and selection (R&S) to select the best medical intervention configuration of K > 1
possible configurations.

Figure 2 Our General Simulation Model's Components
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Model II Definitions
To determine to which type of experiment our simulation model belongs, the
types of experiments should be briefed. There are three types of experiment: the first is
Treatment Comparisons; its purpose is to compare several treatments of a factor (for
example, suppose that one compares three diets and he/she would like to see if they are
different in terms of effectiveness). The second is Variable Screening; (for example,
suppose that one checks a large number of factors, but only a few are important, the
experiment should identify the important, few, factors. The third is Response Suiface
Exploration; after important factors have been identified, their impact on the system is
explored to optimize the response. Our Model is related to the first type of experiments.
Our Simulation output analysis computes measures of performance using the
output mean, variance, confidence interval. Our model can work for comparing
alternative designs in both (1) Simulations with a single model and different input data,
and (2) Simulations with different models.
There are what is called terminating simulations, and non-terminating
simulations. Our model is a terminating simulation. Terminating simulations, in which
there is a natural event that specifies the length of each run; no useful information is
obtained beyond termination; and termination time can be random. Non-terminating
simulations, in which there is no natural event to specify the length of a run.
So, for the effect of initial conditions in terminating simulations, initial conditions
generally affect measures of performance, and initial conditions should be chosen so that
they are representative of the state of the system. Because our model is not a non-
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terminating simulation model, our interest does not lie in the steady-state performance
measures.
Definition: One popular measure of treatment efficacy used in the medical
decision making literature is mean quality-adjusted duration [Weinstein et al. 1980]. This
measure is calculated by weighting the average duration spent in each particular health
state by a quality rate proportional to the desirability of that state. Typically the Well
state is assigned a quality factor of 1, the dead state 0, and other states intermediate
values. The result for each treatment is a duration which, if spent entirely in the Well
state, would be equivalent to receiving the treatment and all its consequences.
Definition: A Stochastic Process is a family of random variables:

(X(t), t <= T}

where t is often interpreted as time; X( t) is the state of the process at time t; T is the index
set of the process.
•

The process can be continuous or discrete. The state space of a stochastic process
is the set of all possible values that X(t) can take on. The state space of the
process is the set of all possible values that the random variables X(t) can assume.

•

Stochastic processes can be classified according to these characteristics: (1) the
state space may be discrete (finite or countable) or continuous. Accordingly, the
stochastic process is called a "discrete-state process" or a "continuous-state
process". Discrete-state processes are also called "chains". (2) The time parameter
is another characteristics of stochastic processes; if the set of points on the time
axis at which changes in X(t) may take place is finite or countable, the stochastic
process is called a "discrete-time process". On the other hand, if X(t) may change
its value anywhere within a finite or infinite interval of the time axis, the process
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is called a "continuous-time process". (3) The statistical dependency among the
values of X(t) for different values of t.

System Setting: Consider some type of treatment for a disease/injury and the
modeling of the effects of that treatment. Suppose that the progression of the
disease/injury following the treatment can be modeled as the progression of the patient
through a series of states, enumerated as: 1,2, .. .n, where n will be defined as the
terminating state. Let

S=

Number of States.

Transition Probability (I, J)

=

the probability that a transition will be made from
State 1 to State J.

Time in State (I,J)

=

the distribution function representing the amount of
time that the patient will spend in State I, given that
a transition will be made to State 1. Note that this
will only be defined if Transition Probability (I, J)
>0. (This will be modeled as an Arena Expression).

QoL (I)

=

Quality of Life

the Quality of Life associated with State I.

=

a time persistent variable representing the quality of
life at a particular point in time.

Then Quality Adjusted Life Years is computed at the end of the simulation run
(when the patient reaches the terminal state) as the integral over time of the Quality of
Life. Each run of the model will yield a different value for QALY s, so 1000 runs will be
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made of the demonstration run. The demonstration run will have 5 states, where State 5
will be defined as the Terminal State, with the following transition:

State:

2

3

4

5

70

30

o

o

10

50

o

10

40

2

40

3

20

30

4

o

20

20

60

5

Model II. Inputs
The inputs of the model are Survival Distributions matrix, Transition Rates
matrix, Patient's Risk assessment factors, Decision Maker's Risk assessment factor, Cost
Discount Factor, Quality of Life, Medical Intervention Costs, and Performance Measures
Weights: (1) the Survival distributions matrix, T, is a one-dimension matrix contains cells
corresponding to patient's health states; each cell of the matrix may contain one value
(median) or a survival distribution. A survival distribution, for a health state sojourn
times, would be any survival distribution such as Exponential, Weibull, Weibull with
accelerated failure time model, and Gamma, etc. (2) Transition Rates matrix (if any): due
to moving from a state of life to another state; transition rates matrix would be a onedimension corresponding to patient's health states. (3) The Patient's Risk assessment
factors (PatientRiskF): for patient's utility assessment, we use Hazen's payoff approach;
this requires the physician to elicit from the patient his or her risk assessment. (4)
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Decision Maker's Risk assessment'factor (DMRiskFactor): this requires the decision maker
to determine his or her risk assessment. (5) Cost discount factor (CostDiscFactor): it is a
factor to compute the treatment cost as a

performance measure (6) Quality of life, QoL,

it is a one-dimension matrix contains QoL values for patient's health states; each cell may
contain a value or a distribution. (7) Medical cost of a health state, C, is a one-dimension
or two-dimension matrix of the health states of life; each cell could contain one value or a
distribution. (8) The importance level values or the weights for the performance
measures, 11 and 12 • The decision maker utility function; 'Lli =1, if Ui are utility
independent, 'Lli < > 1, if Ui are not utility independent.
At the beginning of each simulation, some inputs are initials values. The system outputs
may change by these values; for example, performance measures weights, Ii, that
represent the DM preferences, and also the 1st Health State that the patient begins with.

Model II. Computations
For each replication the simulation system will compute seven formulas:
1. The first formula is to compute the Individual's Attribute Utility Factor of Risk
(IAUFt}, and IAUF 1 = l-exp (- StayTime * PatientRiskF). This is a common
formula for a risk avoider person. The formula fits with an individual faces a
medical intervention that may have some level of risk.
2. The second formula is to compute the Individual's Attribute Utility Factor of Cost
(IAUF2), and IAUF2 = l-exp (-StayTime

* CostDiscFactor). This is a common

formula for a risk avoider person, who faces a costly medical intervention.
3. Quality Adjusted Life Years for each state of life, QALY = QoL
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* IAUF 1* T

4. Adjusted Cost for each state of life, COST = C

* IAVF2 * StayTime

5. Decision's maker utility function on QALY, PerfMeasure], is a risk avoider utility
function; its formula is: V]

= l-exp( - QALy* DMRiskFactor); and O:::;V] :::;1

6. Decision's maker utility function on Cost, PerfMeasurel , is a risk avoider utility
function; its formula is: V 2

= 1 - exp(- X * CostDiscFactor); hence X = 1/(Cost in

$lO,OOOs), Cost <>0, and 0:::;V 2 :::;1
7. Expected decision maker's utility function can be:

E (V)

= WI *UI + W2*U2 if the VI

UI

(pe~treI)

and V2 are utility independent.

= 1 - exp ( - QALY * DM_RiskFactcr)
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Figure 3: Risk avoider utility function on performance measure, QALY
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Figure 4: Risk avoider utility function on performance measure, Treatment Cost

Model II. Outputs
At the end of each simulation, with n replications, the simulation system will output
five performance measures:
I.

Mean of the first performance measure; which is QALY of all health states.

2. Mean of the second performance measure; which is Cost of all health states.
3. Mean of the utility function of the first performance measure on QALY, U1.
4. Mean of the utility function of the second performance measure on Costs, U2.
5. Expected Utility function, E(U), for the decision maker's, on Ul, and U2
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Risk Utility Assessment Used In Model II
Hazen-Pellissier, (1996), presented von Neumann-Morgenstern utility functions
over stochastic trees that allow easy rollback computation. One such utility function is a
risk-sensitive extension of QALY that allows different constant coefficients associated
with risk aversion across health states. Continuous-risk utility assessment protocol, as
described by Hazen (1997), differs from standard preference assessment protocols by
offering choices between alternatives in which risks are present in continuous time. For
medical applications, "continuous-risk utility assessment scenarios are both more realistic
and more familiar than other simpler but more artificial standard gamble approaches".
(Hazen 1997) We use/recommend the same protocol.
To understand how continuous-risk utility assessment works consider the scenario
in Figure # , used to assess a subject's risk attitude about future time spent in morbidity
functional class IV for osteoarthritis of the hip. The subject is asked to determine what

compensating immediate mortality risk p he is willing to gain to decrease his mortality
rate from the high rate J.ll to a lower rate J.lO. The subject's response determined his or her
coefficient of risk aversion for health state: "morbidity functional class IV".

~

vs

Figure 5 Continuous-risk assessment approach, by Hazen 1995.
With this continuous-risk assessment approach, a patient must determine what
chance p at immediate death he/she is willing to accept to improve his future mortality
rate from J.ll to J.l o.

62

Model II Design on Arena Software
Arena is a MS-Windows application, and all the typical Windows features and
operations are available. Also, Arena is fully compatible with common MS-Windows
software, such as MS-Word, and MS-Excel. In Arena models, the basic building blocks
are called modules. These modules are flowchart and data objects that define the process
to be simulated and are selected from panels in the project Bar. Flowchart modules
describe the dynamic processes in the model. Flowchart can be as nodes or health states
through which entities flow, or where entities begin or leave the model.
Flowchart modules are usually connected to each other by somehow. In the Basic
Process panel, the kinds of flowchart modules accessible are several such as Create,
Dispose, Process, Decide, Assign, and Record. Each type of flowchart module has a
distinguishing shape.
Data modules define the characteristics of diverse process elements, such as
entities, resources, and queues. In addition, data modules can set up variables and
expressions and other types of numerical values that relate to the model. Icons for data
modules, in what is called the Project Bar, look like little spreadsheet figures. The Basic
Process panel's data models are several such as Entity, Queue, Resource, and Variable.
Entities don't flow through data modules. Flowchart and Data modules are related to each
other by user defined names for objects (e.g. Variables) that they have in common.
On the following three pages, our general simulation model is displayed on
Arena; and six illustration figures are shown for the model design and setting.
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Ranking and Selection (R&S) Experimental Settings
We employed the ranking and selection procedure of. The goal of this procedure
is to make a statement of the best system; where, "best" refers to the system with the
maximum performance measure of interest for ith alternative treatment and jth replication.
The general approach involves: denoting correct selection with the notation CS.
We want P(CS);;::: p* provided that Ili -Ilj ;;::: d*, where d* defines an indifference amount.
For differences smaller than d* the choice may not be significant. The procedure is
described on pages 30 and 31, We need not assume anything about the variances of Xij,
as it is assumed that they are normally distributed. The procedure is, however, reasonably
robust against departures of this assumption.

Multi-Attribute Utility theory, MAU, (Keeney and Raiffa 1992, Clemen 1991):
MAU is one of the major analytical tools of decision analysis. "A MAU analysis
of alternatives (in our example, medical interventions) explicitly identifies the measures
that are used to evaluate the alternatives, and helps to identify those alternatives that
perform well on a majority of these measures, with a special emphasis on the measures
that are considered to be relatively more important" (Morrice et aI, 1998, page 720).
Our simulation model can run using the decision maker's preferences with the
MAU additive or multiplicative model, In our examples we used two performance
measures, which are UI(QALY) and U2(Treatment cost).

In MAU theory, the additive model is used if the U I and U 2 are utility independent. E(U)
= 11* U I + 12* U2 , where O~ li~ 1; 'i,li =1. And, the model multiplicative model is used
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if the U1 and U2 are not utility independent. E(U)
,where, O:s Ii

:s 1;

'f,

=iJ* U 1 + 12* U 2+ (1-1]-1 2)* U 1* U2

Ii <>1

Supposing RTi is the decision maker's assessed risk tolerance and Ai and Bi are
scaling constants for measure i. a popular form is used in our model (see Clemen 1991, p.
379).The form is single-attribute utility function:

1l.(X)
= A I _ B.e(x,RT,)
I
I
I
Settings: Assume that there are 1<>2 medical intervention, with different
configurations. For

denote a vector of random variables representing the performance measures for
configuration k. Let E[u(Xk)) denote the expected utility (unknown) for configuration k
and let

This denotes the ordered expected utility values. The goal is to select the project
configuration with the largest expected utility E[U(X[k])). If the R&S procedure accurately
identifies the configuration with the largest expected utility, a "correct selection" (CS) is
made.

In the two-stage R&S procedure, such as Law and Kelron, guarantees that the
probability of a correct selection, P {CS} ?..P*, whenever: E [U(X[k])) - E [U(X[k-l]))

=8

p* is specified by the decision maker, and 8 is a practical significance difference
between system X[kJ and X[k-IJo In practice, the selection of 8 depends on the decision of
the decision maker.
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Determ~ning

() Value: Suppose that there is a performance measure X on two

systems, X[kj and X[k-lj, and 8 represents the accepted difference, needed by the decision
maker to distin$uish between the two systems.

8 is computed by t5= 1}.t5} + I2.t52 where t5i

represents a val~e computed by t5i =E [U(X[kj)] - E [U(X[k-lj)], and Ii represents the level of
importance, aSSligned by the decision maker to each performance measure,

~

Ii :S 1

(Butler and Morrice, 1998 & 2001).
For example, suppose that there are two performance measures, Cost and QALY,
measured for two systems. For the system number k and the system number k-1,
t5}=E[u(CoSt[kj)] - E[u(CoSt[k_lj)], and t52 =E[u(QALY[kj)] - E[u(QALY[k_lj)]. Suppose

t5}=0.007, t52=0.O 18 and the decision maker assigned the performance measure "Cost" a
higher level of importance

iJ =0.65, and the performance measure "QALY" a level of

importance I2 =0.35. Then t5 = 0.65*.007 + 0.35*0.018 = 0.011-

In this

s~udy,

we applied our simulation model on an example that compared three

treatment systems related to breast cancer related treatments. We used expected
performance measures on Cost and QALY.
To estall>lish an indifference zone for t5i, its recommended to assess t5i in the units
of the perform~nce measure and then converting to a number on the utility, (0, 1), scale.
We will construct an indifference-zone-preference-zone diagram on the performance
measure, (QALY, and Cost) by using the same procedure utilizing certainty equivalents
on the

single-a~tribute

utility functions.

Having: E[UJ(X[K]})] = UJ(CE[K]})
The indifferenae zone is defined by:
UJ(CE[K]}) - UJ(CErK-l]1)

>= t51
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To estal:lllish the indifference-preference-zone on the original performance
measure: "one <can invert ul(CE[K]l) and uI(CE[K-I]1) and establish an indifference zone
based on CE[K]I and CE[K_I]I. The curve that divides the indifference zone from the
preference

ZOM

is constructed by setting: ul(CE[K]l) - U\(CE[K-I]1) = 8 1 and solving for

CE[K]I' The resultant expression for the curve dividing the indifference zone from the
preference zone is" (Morrice, 2001)

Where, RT is the risk factor, and B is constant, we will sit it to 1 to fit with the risk
avoider utility function, (Morrice, 2001): UlXi)

= 1- e-xi RTi

1110,000
$160,000

Indifference
Zone

:i SI40,OOO

ai!

$120,000

$\00.000

Zone

$10,000

CI{IK-1JoI)

Figure 13 indifference-zone and preference-zone diagram. It is corresponding to 8 1 equal
to 0.2, for the clOst-utility function. This figure is taken from (Morrice, 2001).
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Sensitivity Analysis: Most applications of multiattribute utility theory focus on a
series of sensitivity analyses to set up a sense of the robustness of the recommendations
generated by the MAU model (Dyer et al. 1998). One common technique is to determine
the impact of varying performance measure's weights, which are assessed by the decision
maker, or the patient's risk factors, which are assessed by the decision maker, of the
MAU model. Often this analysis is performed by varying one weight/factor at a time
while the ratios among the other weights/factors are held constant. (Morrice et al. 1999).
We used this approach to study patient's risk factors sensitivity for the breast cancer
treatments application discussed in this research. Though, varying one patient's risk
factors at a time can be misleading because it pays no attention to the potential interaction
that can result from concurrent manipulations of multiple patient's risk factors (Butler et
al. 1997). This matter can be eased by evaluating all probable combinations of
weights/factors via Monte Carlo simulation (Butler et al. 1997). First, in randomly
generating weights/factors for k attributes is to select k-1 independent random numbers
from a uniform distribution on (0, 1). Second, is to rank these numbers. We were able to
use this information in a Monte Carlo simulation sensitivity analysis of the patient's risk
factors.
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3.2.7 Conclusion of the Model (II)
Indeed, there are a number of issues that must be recognized as important for the
success of our approach. Because we use a payoff model this requires elicitation by
decision maker of both a utility function for each measure as well as a "weight," or
indication of relative importance. Techniques for handling these types of elicitations are
available (e.g. Clemen 1991 and Keeney and Raiffa 1976). And for patient's risk
assessment, we recommend what is called continues risk assessment (Hazen 1995,
Hazen-Chang, 1996).
The idea for the methodology outlined, in our simulation model, model II, is
based on interactions of enhanced medical stochastic model, for evaluating multi
treatment outcomes, with real decision makers whose decision inputs are the results of
simulation experiments.
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CHAPTER IV
RESULTS

An enhancement of the stochastic tree model for medical decision
making
Stroke places a huge burden on society in terms of premature death, disability,
and costs of care. Increasingly, the cost-effectiveness of new interventions needs to be
demonstrated before their widespread implementation. Clinical trials are unable to
measure the long-term impact of such new interventions in stroke care, and a modeling
approach is necessary. The Stroke Outcome Model has been developed using enhanced
model of Hazen stochastic tree as a flexible tool for this purpose. Our model is used to
undertake economic analyses of antiplatelet therapy for the prevention of recurrent
strokes, and of stroke unit care and thrombolytic therapy in acute stroke.
CDC- Stroke Facts: Stroke is the third leading cause of death after heart disease
and cancer and a leading cause of serious, long-term disability. In 2002, stroke killed
162,672 people (61 % of them women), accounting for about 1 of every 15 deaths. The
death rate was 56 per 100,000 populations. Stroke death rates are substantially higher for
African Americans than for whites (2002 rates per 100,000 population: 82 for black men,
72 for black women, 54 for white men, and 53 for white women). For other racial and
ethnic groups, 2002 stroke death rates per 100,000 population were 48 for AsianslPacific
Islanders, 41 for Hispanics, and 37 for American Indians/Alaska Natives. Approximately
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50% of stroke deaths occur before the person reaches the hospital. Each year, about
700,000 people suffer a stroke (about 500,000 first attacks and 200,000 recurrent attacks).
From the early 1970s to the early 1990s, the estimated number of non institutionalized
stroke survivors increased from 1.5 million to 2.4 million. Medicare spent $3.6 billion in
1998 on stroke survivors discharged from short-stay hospitals.
Michael Chambers et aI, (2002), developed decision-analytic model that
represents the management of acute stroke and long-term care and prevention of
recurrence for stroke survivors. The latter consists of semi-Markov state-transition
processes, with health states defined by therapy, disability, and occurrence of further
stroke. He concluded that development of this model highlights the need for improved
information on prognosis and resources used by stroke survivors and the importance of
differentiating between economically distinct end points such as death, disabled survival
and non-disabled survival, which may be combined as outcomes in clinical trials.
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Figure 14: Schematic overview of Stroke Outcome Model.
This figure is taken from Michael Chambers et al (2002).
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Michael Chambers et al (2002) developed a long term care/prevention of recurrence
module too; but their long term model does not compute Stroke outcomes.
Hazen on 1992 introduced a continuous-time analog of the Markov-cycle tree, the

stochastic tree, which combines features of decision trees [Raiffa 1968] and stochastic
process transition diagrams. Stochastic tree diagrams not only can depict continuously
distributed temporal uncertainties, but, like decision trees, can be rolled back to
determine optimal decisions.
We introduce a possible extension to the analytical solution, stochastic tree
modeling. In specific, the Weibull accelerated failure time model was utilized instead of
an exponential distribution. This enhancement may increase the stochastic tree modeling
technique's capabilities, by using different state sojourn distribution and by including a
correct boundary difference between experimental treatment and the standard of care.

Example I: the Enhanced Stochastic Tree Model to Compute QALY for Stroke

To calculated the QALY using the WAFT formula, on Chapter 3, we considered
the same stroke model of Hazen, on figure 4, with the same probabilities and rates:
ms=0.05, me=0.065, Pe=0.38, mO=0.0l11, Pb=0.6667; the quality adjustments: v(well)
=1.0, and v(PostBigStrok)=0.2, v(PostSmallStrok)=0.8. In addition, we set for WAFT the
initial values of: Patient's conditions factor <I> = 0.7, A. =0.009, and Patient's Risk

Assessment factor r(y) to 0.12.
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Figure 15: Stochastic Tree Model to Compute QALY for Stroke

Table 7: Results of Stochastic Tree Model to Compute QALY for Stroke

n

0
1
2
3
4

Well
0.0
7.162
7.163
7.163
7.163

Stroke

BigStroke

PostBigStr

BigStroke

Small Stroke

Stroke

«Well

«Stroke

«Big

«PostBi,g

«Stroke

«Small

0.0
0.352
0.353
0.353
0.353

0.0
0.155
0.163
0.164
0.164

0.0
1.361
1.432
1.436
1.436

0.0
0.000
0.105
0.111
0.111

0.0
5.442
5.445
5.445
5.445

0.0
0.000
0.003
0.003
0.003

The symbol «means "reached by"
Table 1 shows that computing the QALY converges, because of Markov process,
to the value of7.163 years. To check the effect of Patient's conditionsfactor, on the
Stroke example, we set Patient's Risk Assessment factor r(y)

=0.12 and three initial

different values to Patient's conditions factor <D = 0.35,0.7, 1.5 and 3, for WAFT. The
QALY results: 8.128,7.947,7.608, and 7.163 respectively.
We introduce a possible extension to the analytical solution, stochastic tree
modeling. In specific, the Weibull accelerated failure time model was utilized instead of
an exponential distribution. This enhancement may increase the stochastic tree modeling
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technique's capabilities, by using different state sojourn distribution and by including a
correct boundary difference between experimental treatment and the standard of care.
However, the stochastic tree model utilizing the Weibull accelerated failure time
model should be restricted to have a memory less property for the rollback computation
with respect to the semi-Markov requirements. On other words, the W AFf model is
used in Hazen's stochastic tree model framework, with an application to study stroke.
The WAFT extends the stochastic tree model capabilities. In addition, inclusion of the
W AFT in the stochastic tree model framework creates a correct boundary difference
between experimental and the non-experimental regimens.
Further work would be an extension to the stochastic tree modeling technique by
integration with simulation, and screening and selection procedures, to have more fully
explore the response of stochastic tree models. To explore this response in a systematic
way, multiple factors must be considered simultaneously with identifying "best"
configurations combinations for some recurrent disease representation on stochastic tree.
The W AFT model is used in Hazen's stochastic tree model framework, with an
application to study stroke. The WAFT extends the stochastic tree model capabilities. In
addition, inclusion of the W AFf in the stochastic tree model framework creates a correct
boundary difference between experimental and the non-experimental regimens.
A stochastic tree model using the W AFT model, by including a patient's health
conditions, may more exactly calculate outcome measures associated with cyclic
disorders or recurrent diseases/injuries. However, this new extended stochastic tree
modeling technique still has a preference summary-memory less property. Future studies
that combine simulations, screening and selection procedures, as well as multi attribute
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utility theory in the stochastic tree model framework are warranted to more fully explore
the robustness of the stochastic tree model technique for recurrent diseases.

4.2. Multiobjectives Simulation-Based Methodologies for Medical

Decision Making
We have applied our simulation model of treatment choice for ductal carcinoma
in situ (DCIS), a precancerous condition whose treatment is controversial (Hazen,

Morrow and Venta 1999). Traditionally, DCIS was a rare disease treated by mastectomy,
but modern mammography has converted this unusual entity into a common pathological
finding (Silverstein et al. 1992, Hiramatsu et al. 1995). Recently the need for surgery as
extensive as mastectomy has been questioned, and alternatives have been proposed such
as lumpectomy, or lumpectomy in conjunction with radiation treatment or the drug
tamoxifen. Here the possible interventions for the patient's ipsilateral breast are portrayed
following diagnosis of DCIS. The possible interventions are mastectomy, lymphectomy
followed by radiation therapy (XRT), or lumpectomy only. The data and the probabilities
such as pSurgDeath (equal to 0.14%) of surgical death under mastectomy are contained
in a spreadsheet tables on the next two pages.

Example:

To utilize our simulation model to select the best DC IS treatment, the data tables required
for the three treatment models are: transition probability matrix, transition rates matrix,
quality of life table, initials for the simulation systems table, annual treatments cost table
(synthetic data), and health states survival distribution table (synthetic data).
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Table 8
Quality of Life (QoL)
State
QoL
Death
0.00
Healthy
1.00
Immediate Cancer
0.70
Invasive Cancer
0.70
Post LymphOnly
1.00
Post LymphRad
0.95
Post Mastectomy
0.90

Table 9
Health State's Stay Time Distributions, in years
State
Survival distributions
Death
0
Healthy
Norm(35,5)
Immediate Cancer
Weib(0.15,0.5)
Invasive Cancer
Epxo(0.08)
Post LymphOnly
Weib(0.00087,3.0)
Post LymphRad
Cont(O,O, .25,4,.50,9,.75,11,1,27)
Post Mastectomy
Norm(7,5)
values are synthetic

Table 10
Annual treatment Cost
State
Dollars
Healthy
$500
Immediate Cancer
$7,000
Invasive Cancer
$5,000
Post LymphOnly
$6,000
Post LymphRad
$4,000
$3,000
Post Mastectomy
values are synthetic

Table 11
Imba
" I VaIues f or th
' IattOn
' system
e Slmu
Initial Value
Variable
Patient's Risk Factor
0.10
0.90
Decision Maker's Risk Factor
0.01
Cost Discount Factor
0.60
WI
0.40
W2
changeable due to model
State of Life
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Table 12
Transition Probability Matrix
State
Death
Healthy
Immediate Cancer
Invasive Cancer
Post LymphOnly
Post LymphRad
Post Mastectomy

Immediate

Invasive

Death

Healthy

Cancer

Cancer

Post
LymphOnly

Post
LymphRad

Post
Mastectomy

0
0
1.00
1.00
0
0
0

0
0
0
0
0.98
0.98
0.98

0
0
0
0
0.02
0.02
0.02

0
0.39
0
0
0
0
0

0
0
0
0
0
0
0

0
0.61
0
0
0
0
0

0
0
0
0
0
0
0

Table 13
Transition Rates
Post
Immediate Invasive
State
Death Healthy
Cancer
Cancer LymphOnly
Death
0
0
0
0
0
Healthy
0
0
0.044
0
0
Immediate Cancer 0.001
0
0
0
0
Invasive Cancer
0.003
0
0
0
0
Post LymphhOnly
0
0
0
0
0
Post LymphRad
0
0
0
0
0
Post Mastectomy
0
0
0
0
0
III case of Lymphh node treatment model, the value 0.044 be 0.017
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Post
LymphRad
0
0
0
0
0
0
0

Post
Mastectomy
0
0
0
0
0
0
0

4.2.2 The Simulation Model on the Stochastic Tree to Compute the Expected Utility
function of QALY and Cost attributes of three Breast Cancer Treatments

Mestectorry

f~-

Figure 16: The Simulation model for Mastectomy
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Figure 17: The Simulation model for Lumpectomy Only
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Figure 18: The Simulation model for Lumpectomy followed by Radiation therapy

4.2.3 Results of our Simulation Model on the Stochastic Tree
For the three DCIS treatments three simulation systems developed, k

= 3, the

above data tables utilized, two utility dependent performance measures, QALY and Cost,
included, the patient's risk assessment factor set to 10%, decision maker's risk
assessment factor set to 90%, initial replications bo set to 20, and the significant
difference J set to 0.006. Using Dudewicz and Dalal (1975) or Rinott, (1978) : the firststage sample means and sample variances, Sj were computed. The sample variances are

n

used to determine the number of macro-replications which must be taken in the second

stage

bi

~ maX{bo{(~i
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h is a function in the number of replications bo, the number of systems k, and b. the value

of h was determined (h=2.431), see Bechhofer, (1995), page 62.
-

_

bi

For b o replications, we computed grand means Y i

=I

y ..

~,i

j=!

bi

= 1,2, ... , k

and selected the system with largest Y i
The macro-replication estimators, ~1' ~2 , ... , ~bi from the ith system are assumed to be
i.i.d. with expectation. If the number of micro-replications is large enough the Central
Limit Theorem (CLT) yields approximate normality for the macro-replication estimators.
Table 14: CDIS pilot experiment; the first stage results

L&Rad L.only Mastec

0.485

0.442

0.492

0.01536 0.0108 0.02402
0.0034
38

0.0024
20

0.0054
94

In stage two, to compute the grand means :Y i ' we re-run the simulation model of
Lumpectomy followed by Radiation therapy (L&Rad) 38 macro-replications, and we re-

run the simulation model of Mastectomy 94 macro-replications. The results:
Table 15: CDIS the second stage results

L&Rad

L.only

Mastec

0.485

0.442

0.487

0.0024

0.0024

0.0029
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We are at least 90% sure that we have made the correct selection (u(l) -

U(2)

>0=0.006);

The best system will be the one with the max average; which is Mastectomy.

4.2.4 Sensitivity Analysis
A sensitivity analysis was made to check whether selecting Mastectomy was
sensitive to the change of patient's and decision maker's risk assessment factors . The
patient's risk assessment factor changed from 10% to 90%, and the decision maker's risk
factor changed from 90% to 10%. For the same three systems of DCIS treatment and for
initial replications bo = 20, the pilot experiment of the first stage is shown on table ##
Table 16: CDIS pilot experiment for the sensitivity analysis; the first stage results
L&Rad L.only lM,lstectomVl

0.4265 0.4345

0.4058

0.0138 0.0092

0.0401

0.0031 0.0020

0.0090

31

20

263

For the final results of the pilot experiment after changing the patient's and the DM's risk
assessment factors, in stage two, we re-run the L&Rad model 31 macro-replications; and
we re-run the mastectomy model 263 macro-replications.
Table 17: CDIS the second stage results, for the sensitivity analysis
L&Rad

L.only

0.4245

0.4345

0.4070

0.0028

0.0020

0.0027
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The results show that the decision was sensitive to the change of patient's risk factor and
the change of DM's risk factor, and the best system is changed to be lumpectomy only
instead of Mastectomy.
To check the effect of patient's illness conditions factor, utilizing Weibull
Accelerated Failure Time model, on the expected utility of lumpectomy followed by
radiation therapy of DCIS, we run the Lymph and Radiation simulation model (figure #)
with different stay time distributions. We set the stay time of the Immediate Cancer and
Invasive Cancer health states to be weibull ($1-., 1), where I-. is the scale parameter (0.08),

and $ is the patient's illness conditions factor, <1>=1,2,3,4, and 5.
For n=30 replications, patient's risk assessment factor 0.50, decision maker' risk
assessment 0.50, and for two utility dependent performance measures, QALY and Cost,
the results is shown on the following figure 19
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Figure 19: Expected utility of Lymph Radiation Therapy. The curve shows that the
expected utility changes when the patient's illness conditions factor changes.
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4.3. Discussi~m and Conclusion
The imnortance of Hazen's stochastic tree was mentioned in the technical report,
by Prof. Keefer! et al (2002), "Summary of Decision Analysis Applications in the
Operations

Res~arch

Literature, 1990-2001". The report declared that the work of Hazen

et al. (1998), who provided an introduction to stochastic trees and related software to be
used in medical decision making, is one of the application that presented significant detail
about a particu~ar decision analysis methodological issue (Keefer, 2002). However, there
are still no wid¢ly accepted techniques for incorporating variability in the estimates of the
parameters/ pe~formance measures of a decision tree.
For cOn}plex stochastic decision trees with random variable parameters,
simulation app~ication of such a system is important in order to introduce key
components an~ processes that provide a source of data for reliable implementation. One
of the many prqblems for which simulation has been found to be a useful and powerful
tool is designing and operating stochastic models, such as probabilistic trees. The
stochastic tree

~s

a model which could integrate of simulations, survival analysis

approaches, an<ll ranking-selection procedures (Hazen, 1992, Hazen & Pellissier, 1996). It
would be bene~icial to add development to the stochastic tree for decision analyses for
medical

interv~ntion

In this

in recurrent diseases.

r~search,

we used parametric survival models, such as the Weibull

Accelerated Failure Time Model, to include patient's conditional survival probability
accurately. Moteover, in our enhanced model on Hazen's stochastic tree, we combined
the Wei bull Accelerated Failure Time model into our model to fill the gap between the
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experimental and actual/current medical intervention for recurrent diseases or injury.
Also, our multi~objective simulation-based model has the facility to use not only
exponential distribution for states sojourn but also the parametric survival models too.
"There have been fewer methods proposed and thus little software developed for
analyzing multiple test data, due to difficulties relating to the covariances among the
variables" Westfall et al. (1999). Our multi-objective simulation-based model developed
for analyzing multiple performance measure/test without difficulties relating to the
covariances among the variables.
Our multi-objective simulation-based model gives the facility to the decision
maker to set his/her policy through the use of Multi-Attributes Utility theory (MAU).
Moreover, the use of MAU is appropriate for multi-objective functions; this would be an
advantage over the dynamic programming principle. In the analysis, utility theory
involves gathering the measures into a "Unified-Measure" of the desirability of each
alternative. Utility theory provides the basis for the appropriate approach to combine the
apparently unlike measures.
Our simulation model is easy to use and compute in chronic cases, when the
chance of moving between health states increases with age. It fits with the fact that aging
increases the risk of transition from a healthy state to one of sickness, thereby violating
the constant state-transition probability assumption in Markov chains (e.g. using the
Weibull Accelerated Failure Time Model). Our system can behave as Markov processes
that are used to model disease over longer time periods. In addition to behaving similarly
to the pure Markov model our simulation model fits with the semi-Markov process
model. It is a model useful in analyzing complex dynamic systems, and its transition rates
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in a particular state depend on the time already spent in that state (sojourn time), but they
do not depend on the path by which the present state was reached.

In our simulation model, we used the MAU to unify multi tests (multiperformance measures) into one scale (Morrice, 1998). Thus we utilized a RankingSelection procedure of Rinott, (1978), to select the system with the largest expected
performance measures (Bechhofer 1995, Kim-Nelson 2001, Nelson-Miler 1995).
The weights represent another confounder and affect the relative importance of a
performance measures, its impact on the variation, and its impact on the computing
should be tested by sensitivity analysis. Our example, of three medical interventions for
breast cancer treatment, demonstrates that our approach can be applied to realistic
medical problems in which simulation is utilized.
The idea presented by Chick et al (1998, 2001), who use a Bayesian technique to
determine the number of additional replications required to reduce the risk of an incorrect
selection, one could extend our simulation based methodology to include their work;
however, their work focuses on a single criterion. That would ease some of the
computational burden associated with the used R&S procedures. Using of common
random numbers would facilitate variance reduction to our work that has combination
with R&S procedures (Nelson et al 1995 and Goldsman et al 1998).
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4.4. Our approach Advantages.
Applying R&S procedures on MAD theory outputs allows good performance on
one criterion to compensate for poor performance on another, and we assess the
comparative importance of each criterion. Previous work on multivariate R&S
procedures has been limited by the lack of a trade-off method that allows the decision
maker to combine explicitly different performance measures (Gupta, 1979).
Our approach closely relates to the common medical-business management of
assigning preferences to different performance measures. Similar to the solution achieved
by Morrice et al (1998 and 2001), in industry, our solution does not require complications
like a covariance matrix, which was used by Gupta (1979).
Our approach leads to a reasonable decision; for example, it avoids Kim and Lin
(1999) approach that in some situations focuses on maximizing the poorest performing
criterion (they used the MaxiMin approach). And, unlike Kim and Lin, we do not
perform "several approaches for the final decision"
Certainly, there are several issues that must be recognized as important for the
success of our approach. Because we use a payoff model this requires elicitation by
decision maker of both a utility function for each measure, for example: QALY and
COST, as well as a "weight," or indication of relative importance. Techniques for
handling these types of elicitations are available (e.g. Clemen 1991 and Keeney and
Raiffa 1976). And for patient's utility assessment, we use Hazen's payoff approach; this
requires the physician to elicit from the patient his or her risk assessment.
The idea for the methodology outlined in this research is based on integration of
an enhanced medical stochastic model, for evaluating multi medical
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intervention/treatment outcomes, with real decision makers, who use decision inputs
computed by simulation experiments combining patient's preferences, condition, and
health states.
Our work result represents a combination of two sound theories: multi-attribute
utility theory and ranking and selection with an enhancement/extension of Hazen's
stochastic tree model using simulation. This synthesis extends the use of medical
stochastic models, simulation, and ranking-selection literature by accommodating
multiple criteria, and provides another application area for multi-attribute utility theory.
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